<DOC>
	<DOC>NCT01307488</DOC>
	<brief_summary>A switch to a regimen consisting of ATV/RTV 300/100 mg QD + 3TC 300 mg QD in HIV-1 infected subjects in their first antiretroviral regimen and who are virologically suppressed on a regimen which consists of 2 NRTIs + any 3rd agent, is non-inferior to continue or switch to ATV/RTV 300/100 mg QD + 2 optimized NRTIs for maintenance of virological suppression.</brief_summary>
	<brief_title>Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy</brief_title>
	<detailed_description>Clinical Trial, phase IV, randomized, open label, multicenter with approved drugs in their use conditions. A switch to a regimen consisting of ATV/RTV 300/100 mg QD + 3TC 300 mg QD in HIV-1 infected subjects in their first antiretroviral regimen and who are virologically suppressed on a regimen which consists of 2 NRTIs + any 3rd agent, is non-inferior to continue or switch to ATV/RTV 300/100 mg QD + 2 optimized NRTIs for maintenance of virological suppression.</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Signature of informed consent At least 18 years old Patients on their 1st ARV treatment consisting on 2 NRTIs + 1 third agent for at least 1 year Undetectable viral load for at least 6 months prior to inclusion in the study (VL&lt;50 c/mL in 2 determinations 6 months apart; blips are not allowed). Requirement of ARV treatment change due to toxicity, intolerance or simplification. Clinically stable. Pregnant women or women who plan to get pregnant during the study. Breast feeding History of change of any ARV treatment component for any reason 4 months prior to the inclusion in the trial History of ARV treatment change due to virological failure History of confirmed virological failure defined as one single VL &gt;400 c/mL or at least 2 VL between 50 and 400 c/mL one year after an indetectable VL was achieved. Absence of HIV genotype prior to ARV treatment initiation. Resistance mutation to any of the study drugs (ATV, RTV, 3TC) HBV infection. History of toxicity or intolerance to ATV, RTV or 3TC. Gilbert's syndrome. Use of contraindicated drugs. Lab abnormalities grade 4.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>HIV</keyword>
	<keyword>AIDS</keyword>
	<keyword>Atazanavir</keyword>
	<keyword>Simplification</keyword>
</DOC>